These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 8449229)
21. MS-551 and KCB-328, two class III drugs aggravated adrenaline-induced arrhythmias. Xue Y; Yamada C; Aye NN; Hashimoto K Br J Pharmacol; 1998 Aug; 124(8):1712-8. PubMed ID: 9756388 [TBL] [Abstract][Full Text] [Related]
22. Effects of a new antiarrhythmic drug, SD-3212, on canine ventricular arrhythmia models. Hirasawa A; Haruno A; Matsuzaki T; Hashimoto K Jpn Heart J; 1992 Nov; 33(6):851-61. PubMed ID: 1299746 [TBL] [Abstract][Full Text] [Related]
23. Antiarrhythmic effects of a novel class III drug, KCB-328, on canine ventricular arrhythmia models. Xue Y; Tanabe S; Nabuchi Y; Hashimoto K J Cardiovasc Pharmacol; 1998 Aug; 32(2):239-47. PubMed ID: 9700986 [TBL] [Abstract][Full Text] [Related]
24. Effects of dofetilide, a class III antiarrhythmic drug, on various ventricular arrhythmias in dogs. Chen J; Xue Y; Eto K; Ni C; Hashimoto K J Cardiovasc Pharmacol; 1996 Oct; 28(4):576-84. PubMed ID: 8891885 [TBL] [Abstract][Full Text] [Related]
25. Antiarrhythmic effects of an aconitine-like compound, TJN-505, on canine arrhythmia models. Arita J; Xue YX; Aye NN; Fukuyama K; Wakui Y; Niitsu K; Maruno M; Siying C; Hashimoto K Eur J Pharmacol; 1996 Dec; 318(2-3):333-40. PubMed ID: 9016923 [TBL] [Abstract][Full Text] [Related]
26. Quantitative analysis of the antiarrhythmic effect of drugs on canine ventricular arrhythmias by the determination of minimum effective plasma concentrations. Hashimoto K; Shibuya T; Satoh H; Imai S Jpn Circ J; 1983 Jan; 47(1):92-7. PubMed ID: 6827775 [TBL] [Abstract][Full Text] [Related]
27. Effective plasma concentrations of aprindine in canine ventricular arrhythmias. Hashimoto K; Komori S; Ishii M; Kamiya J J Cardiovasc Pharmacol; 1984; 6(1):12-9. PubMed ID: 6199593 [TBL] [Abstract][Full Text] [Related]
28. Arrhythmia models for drug research: classification of antiarrhythmic drugs. Hashimoto K J Pharmacol Sci; 2007 Apr; 103(4):333-46. PubMed ID: 17409630 [TBL] [Abstract][Full Text] [Related]
29. In vivo antiarrhythmic profile of AP-792 assessed in different canine arrhythmia models. Takahara A; Hirasawa A; Dohmoto H; Shoji M; Yoshimoto R; Sugiyama A; Hashimoto K Jpn J Pharmacol; 2001 Sep; 87(1):21-6. PubMed ID: 11676194 [TBL] [Abstract][Full Text] [Related]
30. [Antiarrhythmic effects of DHA-As on ventricular arrhythmias in rat and dog hearts]. Xue Y; Aye NN; Hashimoto K Nihon Yakurigaku Zasshi; 1997 Oct; 110 Suppl 1():165P-170P. PubMed ID: 9503426 [TBL] [Abstract][Full Text] [Related]
31. Antiarrhythmic plasma concentrations of mexiletine on canine ventricular arrhythmias. Hashimoto K; Ishii M; Komori S J Cardiovasc Pharmacol; 1984; 6(2):213-9. PubMed ID: 6200706 [TBL] [Abstract][Full Text] [Related]
32. Antiarrhythmic plasma concentrations of NIK-244 on canine ventricular arrhythmias. Hashimoto K; Matsuzaki T; Haruno A J Cardiovasc Pharmacol; 1989 Dec; 14(6):892-8. PubMed ID: 2481779 [TBL] [Abstract][Full Text] [Related]
33. Effects of antiarrhythmic drugs on canine ventricular arrhythmia models: which electrophysiological characteristics of drugs are related to their effectiveness? Hashimoto K; Haruno A; Matsuzaki T; Sugiyama A; Akiyama K Cardiovasc Drugs Ther; 1991 Aug; 5 Suppl 4():805-17. PubMed ID: 1657110 [TBL] [Abstract][Full Text] [Related]
34. Effects of a cardioselective M2 receptor antagonist, AF-DX 116, on ventricular arrhythmias in dogs. Naito H; Furukawa Y; Hashimoto K Heart Vessels; 1997; 12(5):229-33. PubMed ID: 9846808 [TBL] [Abstract][Full Text] [Related]
35. Effects of a new forskolin derivative, NKH477, on canine ventricular arrhythmia models. Hirasawa A; Awaji T; Hosono M; Haruno A; Hashimoto K J Cardiovasc Pharmacol; 1993 Dec; 22(6):847-51. PubMed ID: 7509903 [TBL] [Abstract][Full Text] [Related]
36. Antiarrhythmic effect of oxprenolol on halothane-epinephrine and coronary ligation induced ventricular arrhythmias in beagle dogs. Hashimoto K; Tsukada T; Matsuda H; Matsubara I; Imai S Jpn J Pharmacol; 1978 Aug; 28(4):535-44. PubMed ID: 32416 [TBL] [Abstract][Full Text] [Related]
37. Antiarrhythmic and cardiohemodynamic effects of a novel Ca(2+) channel blocker, AH-1058, assessed in canine arrhythmia models. Takahara A; Sugiyama A; Dohmoto H; Yoshimoto R; Hashimoto K Eur J Pharmacol; 2000 Jun; 398(1):107-12. PubMed ID: 10856454 [TBL] [Abstract][Full Text] [Related]
38. Effects of azimilide, a KV(r) and KV(s) blocker, on canine ventricular arrhythmia models. Xue Y; Yamada C; Chino D; Hashimoto K Eur J Pharmacol; 1999 Jul; 376(1-2):27-35. PubMed ID: 10440086 [TBL] [Abstract][Full Text] [Related]
39. Effects of KT-362, a new Na and Ca influx and Ca release inhibitor, on canine ventricular arrhythmias. Hashimoto K; Watanabe K; Mochizuki S; Tomiyama A Jpn J Pharmacol; 1989 Dec; 51(4):475-82. PubMed ID: 2559225 [TBL] [Abstract][Full Text] [Related]
40. QT-prolonging class I drug, disopyramide, does not aggravate but suppresses adrenaline-induced arrhythmias. Comparison with cibenzoline and pilsicainide. Miyamoto S; Zhu B; Teramatsu T; Aye NN; Hashimoto K Eur J Pharmacol; 2000 Jul; 400(2-3):263-9. PubMed ID: 10988343 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]